Merck & Co will start late-stage CMV prevention testing of first-in-class viral terminase complex inhibitor in renal transplant patients during the first half of 2018, following its launch for stem cell transplant recipients.
Merck & Co. Inc. plans to press its first-mover advantage in the prevention of cytomegalovirus (CMV) infection and disease in transplant patients by testing newly launched Prevymis (letermovir) in other indications.
Orphan drug Prevymis was launched in the US in December and will be soon in Europe after being approved in both regions for the prevention of CMV reactivation and disease in patients receiving
The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
